aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting [Yahoo! Finance]
aTyr Pharma, Inc. (ATYR)
Company Research
Source: Yahoo! Finance
placebo steroid withdrawal was higher than expected, but the 5 mg/kg dose showed statistically significant quality-of-life improvements (KSQ lung), a positive steroid-free+KSQ composite with dose response, preserved FVC versus placebo, and a favorable safety profile. aTyr has an FDA Type C meeting in mid-April to review EFZO-FIT; management says a filing would be “very challenging” after the primary miss and is preparing for the possibility the FDA will request another study, with any future trial likely to emphasize quality-of-life and pulmonary function endpoints by patient phenotype. The company's platform leverages tRNA synthetase fragments to modulate innate immunity in inflammatory ILDs, is advancing ATYR0101 as a potential anti-fibrotic and completing the Phase 2 EFZO-CONNECT scleroderma-ILD study, and reported roughly $80 million in cash at year-end. Interested in aTyr Pharma, Inc.? Here are five stocks we like better. aTyr Pharma (NASDAQ:ATYR) CEO Sanjay Shukla outlin
Show less
Read more
Impact Snapshot
Event Time:
ATYR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATYR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATYR alerts
High impacting aTyr Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATYR
News
- aTyr Pharma (ATYR) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ATYR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hoMarketBeat
- aTyr Pharma (ATYR) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate UpdateGlobeNewswire
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
ATYR
Earnings
- 11/6/25 - Miss
ATYR
Sec Filings
- 3/12/26 - Form PRE
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- ATYR's page on the SEC website